Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.1.243

Association Between C-reactive Protein and Risk of Cancer: A Meta-analysis of Prospective Cohort Studies  

Guo, Yong-Zhong (Department of Respiratory Medicine, Xuzhou Central Hospital, Affiliated Xuzhou Hospital of Medical College of Southeast University)
Pan, Lei (Guangzhou Institute of Respiratory Diseases, State Key Lab of Respiratory Diseases, The First Affiliated Hospital of Guangzhou Medical College)
Du, Chang-Jun (Department of Respiratory Medicine, Xuzhou Central Hospital, Affiliated Xuzhou Hospital of Medical College of Southeast University)
Ren, Dun-Qiang (Department of Respiratory Medicine, The Affiliated Hospital of Medical College Qingdao University)
Xie, Xiao-Mei (Department of Radiotherapy, Xuzhou Central Hospital, Affiliated Xuzhou Hospital of Medical College of Southeast University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.1, 2013 , pp. 243-248 More about this Journal
Abstract
Background: Associations between elevated C-reactive protein (CRP) and cancer risk have been reported for many years, but the results from prospective cohort studies remains controversial. A meta-analysis of prospective cohort studies was therefore conducted to address this issue. Methods: Eligible studies were identified by searching the PubMed and EMBASE up to October 2012. Pooled hazard ratios (HR) was calculated by using random effects model. Results: Eleven prospective cohort studies involving a total of 194,796 participants and 11,459 cancer cases were included in this meta-analysis. The pooled HR per natural log unit change in CRP was 1.105 (95% confidence interval (CI): 1.033-1.178) for all-cancer, 1.308 (95% CI: 1.097-1.519) for lung cancer, 1.040 (95% CI: 0.910-1.170) for breast cancer, 1.063 (95% CI: 0.965-1.161) for prostate cancer, and 1.055 (95% CI: 0.925-1.184) for colorectal cancer. Dose-response analysis showed that the exponentiated linear trend for a change of one natural log unit in CRP was 1.012 (95% CI: 1.006-1.018) for all-cancer. No evidence of publication bias was observed. Conclusions: The results of this meta-analysis showed that the elevated levels of CRP are associated with an increased risk of all-cancer, lung cancer, and possibly breast, prostate and colorectal cancer. The result supports a role of chronic inflammation in carcinogenesis. Further research effort should be performed to identify whether CRP, as a marker of inflammation, has a direct role in carcinogenesis.
Keywords
C-reactive protein; cancer; cohort studies; meta-analysis;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Van Hemelrijck M, Holmberg L, Garmo H, et al (2011). Association between levels of C-reactive protein and leukocytes and cancer: three repeated measurements in the Swedish AMORIS study. Cancer Epidemiol Biomarkers Prev, 20, 428-37.   DOI   ScienceOn
2 Zhang SM, Buring JE, Lee IM, Cook NR, Ridker PM (2005). C-reactive protein levels are not associated with increased risk for colorectal cancer in women. Ann Intern Med, 142, 425-32.   DOI   ScienceOn
3 Zhang SM, Lin J, Cook NR, et al (2007). C-reactive protein and risk of breast cancer. J Natl Cancer Inst, 99, 890-4.   DOI   ScienceOn
4 Lubin JH, Alavanja MC, Caporaso N, et al (2007). Cigarette smoking and cancer risk: modeling total exposure and intensity. Am J Epidemiol, 166, 479-89.   DOI   ScienceOn
5 Mantovani A, Allavena P, Sica A, Balkwill F (2008). Cancer-related inflammation. Nature, 454, 436-44.   DOI   ScienceOn
6 Moore MM, Chua W, Charles KA, Clarke SJ (2010). Inflammation and cancer: causes and consequences. Clin Pharmacol Ther, 87, 504-8.   DOI   ScienceOn
7 Orsini N, Bellocco R, Greenland S (2006). Generalized least squares for trend estimation of summarized dose-response data. Stata J, 6, 40-57.
8 Otani T, Iwasaki M, Sasazuki S, Inoue M, Tsugane S (2006). Plasma C-reactive protein and risk of colorectal cancer in a nested casecontrol study: Japan Public Health Center-based prospective study. Cancer Epidemiol Biomarkers Prev, 15, 690-5.   DOI   ScienceOn
9 Pearson TA, Mensah GA, Alexander RW, et al (2003). Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 107, 499-511.   DOI   ScienceOn
10 Pierce BL, Biggs ML, DeCambre M, et al (2009). C-reactive protein, interleukin-6, and prostate cancer risk in men aged 65 years and older. Cancer Causes Control, 20, 1193-203.   DOI   ScienceOn
11 Pine SR, Mechanic LE, Enewold L, et al (2011). Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst, 103, 1112-22.   DOI   ScienceOn
12 Platz EA, De Marzo AM, Erlinger TP, et al (2004). No association between pre-diagnostic plasma C-reactive protein concentration and subsequent prostate cancer. Prostate, 59, 393-400.   DOI   ScienceOn
13 Prizment AE, Anderson KE, Visvanathan K, Folsom AR (2011). Association of inflammatory markers with colorectal cancer incidence in the atherosclerosis risk in communities study. Cancer Epidemiol Biomarkers Prev, 20, 297-307.   DOI   ScienceOn
14 Proctor MJ, Talwar D, Balmar SM, et al (2010). The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study. Br J Cancer, 103, 870-6.   DOI   ScienceOn
15 Sgambato A, Cittadini A (2010). Inflammation and cancer: a multifaceted link. Eur Rev Med Pharmacol Sci, 14, 263-8.
16 Ben-Baruch A (2003). Host microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res, 5, 31-6.   DOI
17 Siemes C, Visser LE, Coebergh JW, et al (2006). C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol, 24, 5216-22.   DOI   ScienceOn
18 Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P (2006). Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev, 15, 381-4.   DOI   ScienceOn
19 Tsilidis KK, Branchini C, Guallar E, et al (2008). C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer, 123, 1133-40.   DOI   ScienceOn
20 Bianchini F, Kaaks R, Vainio H (2002). Overweight, obesity, and cancer risk. Lancet Oncol, 3, 565-74.   DOI   ScienceOn
21 Bochud M, Rousson V (2010). Usefulness of Mendelian randomization in observational epidemiology. Int J Environ Res Public Health, 7, 711-28.   DOI   ScienceOn
22 Chaturvedi AK, Caporaso NE, Katki HA, et al (2010). C-reactive protein and risk of lung cancer. J Clin Oncol, 28, 2719-26.   DOI   ScienceOn
23 Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009). Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis, 30, 1073-81.   DOI   ScienceOn
24 Dos SSI, De Stavola BL, Pizzi C, Meade TW (2010). Circulating levels of coagulation and inflammation markers and cancer risks: individual participant analysis of data from three long-term cohorts. Int J Epidemiol, 39, 699-709.   DOI   ScienceOn
25 Gur T, Demir H, Kotan MC (2011). Tumor markers and biochemical parameters in colon cancer patients before and after chemotherapy. Asian Pac J Cancer Prev, 12, 3147-50.
26 Duval S, Tweedie R (2000). Trim and fill: A simple funnel-plotbased method of testing and adjusting for publication bias in meta-analysis. Biometrics, 56, 455-63.   DOI   ScienceOn
27 Greenland S, Longnecker MP (1992). Methods for trend estimation from summarized dose-response data, with applications to metaanalysis. Am J Epidemiol, 135, 1301-9.
28 Gunter MJ, Stolzenberg-Solomon R, Cross AJ, et al (2006). A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res, 66, 2483-7.   DOI   ScienceOn
29 Haverkamp J, Charbonneau B, Ratliff TL (2008). Prostate inflammation and its potential impact on prostate cancer: a current review. J Cell Biochem, 103, 1344-53.   DOI   ScienceOn
30 Heikkila K, Harris R, Lowe G, et al (2009). Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control, 20, 15-26.   DOI   ScienceOn
31 Heikkila K, Silander K, Salomaa V, et al (2011). C-reactive proteinassociated genetic variants and cancer risk: findings from FINRISK 1992, FINRISK 1997 and Health 2000 studies. Eur J Cancer, 47, 404-12.   DOI   ScienceOn
32 Helzlsouer KJ, Erlinger TP, Platz EA (2006). C-reactive protein levels and subsequent cancer outcomes: results from a prospective cohort study. Eur J Cancer, 42, 704-7.   DOI   ScienceOn
33 Higgins JPT, Sally Green P (2011). Cochrane handbook for systematic reviews of interventions. New York: John Wiley & Sons.
34 Allin KH, Bojesen SE, Nordestgaard BG (2009). Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol, 27, 2217-24.   DOI   ScienceOn
35 Il'Yasova D, Colbert LH, Harris TB, et al (2005). Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev, 14, 2413-8.   DOI   ScienceOn
36 Lee S, Choe JW, Kim HK, Sung J (2011). High-sensitivity C-reactive protein and cancer. J Epidemiol, 21, 161-8.   DOI
37 Aleksandrova K, Jenab M, Boeing H, et al (2010). Circulating C-reactive protein concentrations and risks of colon and rectal cancer: a nested case-control study within the European Prospective Investigation into Cancer and Nutrition. Am J Epidemiol, 172, 407-18.   DOI   ScienceOn
38 Allin KH, Nordestgaard BG, Zacho J, Tybjaerg-Hansen A, Bojesen SE (2010). C-reactive protein and the risk of cancer: a mendelian randomization study. J Natl Cancer Inst, 102, 202-6.   DOI   ScienceOn
39 Allin KH, Bojesen SE, Johansen JS, Nordestgaard BG (2012). Cancer risk by combined levels of YKL-40 and C-reactive protein in the general population. Br J Cancer, 106, 199-205.   DOI   ScienceOn
40 Austin PC, Anderson GM, Cigsar C, Gruneir A (2012). Comparing the cohort design and the nested case-control design in the presence of both time-invariant and time-dependent treatment and competing risks: bias and precision. Pharmacoepidemiol Drug Saf, 21, 714-24.   DOI   ScienceOn
41 Babu SN, Chetal G, Kumar S (2012). Macrophage migration inhibitory factor: a potential marker for cancer diagnosis and therapy. Asian Pac J Cancer Prev, 13, 1737-44.   DOI   ScienceOn
42 Balkwill F, Mantovani A (2001). Inflammation and cancer: back to Virchow? Lancet, 357, 539-45.   DOI   ScienceOn